ClinicalTrials.Veeva

Menu

Olmesartan Medoxomil in Atherosclerosis

Daiichi Sankyo logo

Daiichi Sankyo

Status and phase

Completed
Phase 3

Conditions

Atherosclerotic Cardiovascular Disease
Essential Hypertension

Treatments

Drug: olmesartan medoxomil
Drug: Hydrochlorothiazide
Drug: Olmesartan medoxomil
Drug: atenolol
Drug: Atenolol

Study type

Interventional

Funder types

Industry

Identifiers

NCT00185185
SE-866/27

Details and patient eligibility

About

This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.

Enrollment

165 patients

Sex

All

Ages

35 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg
  • Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or TIA
  • Intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl

Exclusion criteria

  • Body mass index > 30
  • Any type of known secondary hypertension
  • Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (< 50/min)
  • Obstructive pulmonary disease
  • Claudicatio intermittens
  • History or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial
  • Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy
  • Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening
  • Treatment with disallowed medication
  • Pregnant or breastfeeding females or females of childbearing potential without adequate contraception
  • History of alcohol and/or drug abuse

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

165 participants in 2 patient groups

1
Experimental group
Description:
olmesartan medoxomil
Treatment:
Drug: Hydrochlorothiazide
Drug: Olmesartan medoxomil
2
Active Comparator group
Description:
atenolol
Treatment:
Drug: Hydrochlorothiazide
Drug: Atenolol

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems